Bengaluru-based Indian biopharmaceutical company Biocon is set to declare its Q3FY20 numbers today. Here are the key things to keep in mind ahead of the results:
The revenue is expected to grow by around 12 percent.
EBITDA is likely to be up around 23 percent.
Margins are expected at 27 percent.
Profit is likely to grow at a rate of 10 percent.
For this quarter, the impact of the launch of Trastuzumab will be seen.
Among the key things to watch out for will be the branded generic segment.
Management commentary with regards to insulin Glargine will also be crucial.